Communiqués Absci Corporation

Actions

ABSI

US00091E1091

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
9,650 ^USD	+4,10%		+17,54%	+176,50%

16/09	Transcript : Absci Corporation Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 07:45 AM
28/08	Au-delà de la balance : les hommes se tournent vers les cliniques esthétiques pour parachever leur perte de poids	RE

Communiqués

01/09	Absci to Participate in Upcoming Investor Conferences	GL
11/08	Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results	GL
24/07	A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed	AQ
14/07	Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026	GL
24/06	Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors	GL
24/06	Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)	GL
16/06	The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It	AQ
10/06	OpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug Discovery	AQ
20/05	Absci to Participate in Upcoming Investor Conferences	GL
08/05	Absci : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results	GL
07/05	Absci : Corporate Presentation, May 2026	PU
05/05	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
23/04	Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026	GL
08/04	Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference	GL
24/03	Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results	GL
24/03	Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic	GL
24/03	Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic	AQ
06/03	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
03/03	Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer	GL
24/02	Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026	GL
17/02	Absci to Participate in Upcoming Investor Conferences	GL
16/12	Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference	GL
16/12	Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference	AQ
12/12	AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave	AQ